| Assessment Status | Rapid Review Complete |
| HTA ID | 23017 |
| Drug | Relugolix |
| Brand | Orgovyx® |
| Indication | Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. |
| Assessment Process | |
| Rapid review commissioned | 14/03/2023 |
| Rapid review completed | 31/03/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
